Stem Cell Glossary & Terminology
Search and understand key terms used in stem cell research.
Adult stem cell
An undifferentiated cell found in a differentiated tissue that can renew itself and, with limits, give rise to the specialized cell types of that tissue. Also called a somatic stem cell.
Advanced Therapy Medicinal Product (ATMP)
In the European Union, a medicine based on genes, cells, or tissues, including gene therapy, somatic-cell therapy, and tissue-engineered products. ATMPs are regulated under Regulation (EC) No 1394/2007.
Allogeneic
Describes cells or tissues taken from a donor and given to a different person. Allogeneic products can be manufactured in larger batches but may require immune matching or immune suppression.
Apheresis
A procedure that removes whole blood from a donor or patient, separates out a desired component such as blood-forming stem cells, and returns the remaining blood. It is commonly used to collect cells for transplant.
Autologous
Describes cells or tissues taken from a person and given back to the same person. Autologous therapies avoid donor immune mismatch but are made one patient at a time.
Base editing
A form of gene editing that chemically changes one DNA base into another at a targeted site without cutting both strands of the DNA double helix. It is used to correct or introduce single-base mutations.
Biologics License Application (BLA)
The request a company files with the U.S. Food and Drug Administration for permission to market a biologic product, such as a cell or gene therapy, in interstate commerce after clinical testing.
Blastocyst
A hollow ball of cells formed early in mammalian development, before implantation. It contains an outer trophectoderm layer and an inner cell mass from which embryonic stem cells can be derived.
CAR-T / CAR-NK
Immune cells engineered to carry a chimeric antigen receptor (CAR) that helps them recognize and kill target cells, most often in cancer. Some experimental platforms start from induced pluripotent stem cells rather than a patient’s own cells.
Cell therapy
Treatment that introduces whole cells into a patient to restore function or fight disease. Blood-forming stem cell transplants and some engineered immune-cell products are examples.
Clinical trial phases
Staged studies of a medical product in people. Phase 1 mainly assesses safety and dosing, Phase 2 explores effectiveness and side effects, Phase 3 compares the product with standard care in larger groups, and Phase 4 continues monitoring after approval.
Conditioning regimen
Chemotherapy, radiation, or both given before a blood-forming stem cell transplant to reduce disease and make room for the new cells to engraft.
Cord blood banking
Collection and storage of blood-forming stem cells from the umbilical cord and placenta after birth, either for a family’s possible later use or for public donation.
CRISPR gene editing
A method that uses a guide RNA and a Cas enzyme, often Cas9, to cut DNA at a chosen sequence so cells can disable, correct, or insert genetic material. Related tools include base editing and prime editing.
Cryopreservation
Freezing cells or tissues, usually with a protective agent, so they can be stored and later thawed for research or clinical use while keeping as many cells viable as possible.
Differentiation
The process by which a less specialized cell becomes a more specialized cell type, such as a stem cell becoming a blood, nerve, or muscle cell.
Directed differentiation
Laboratory methods that use defined signals, such as growth factors, to guide pluripotent or other stem cells toward a chosen specialized cell type.
Embryoid body
A three-dimensional aggregate of pluripotent stem cells grown in culture that can begin forming cell types from the three embryonic germ layers.
Embryonic stem cell (ESC)
A pluripotent stem cell derived from the inner cell mass of a blastocyst. Embryonic stem cells can renew themselves in culture and form cell types from all three germ layers.
Engraftment
The point after transplant when donor blood-forming stem cells settle in the bone marrow and begin making new blood cells at sustained levels.
Gene therapy
Treatment that introduces, removes, or changes genetic material in a person’s cells to treat disease. Some products deliver a gene directly; others modify cells outside the body and then infuse them.
Gene-edited cell therapy
A treatment in which a patient’s or donor’s cells are genetically modified, for example with CRISPR, before being returned to the patient. Casgevy for sickle cell disease is one approved example.
Good Manufacturing Practice (GMP)
Quality rules for how drugs and biologics are made, tested, and controlled so that products are safe, pure, and consistent from batch to batch.
Graft-versus-host disease (GVHD)
A complication of allogeneic transplant in which donor immune cells attack the recipient’s tissues. Some mesenchymal stromal cell products have been studied as treatments for GVHD.
HCT/P
Human cells, tissues, or cellular and tissue-based products regulated by the U.S. FDA. Products that are only minimally manipulated and for homologous use may fall under section 361 of the Public Health Service Act; others generally require section 351 approval as biologics.
Hematopoietic stem cell (HSC)
A blood-forming stem cell that can renew itself and give rise to all red cells, white cells, and platelets. HSCs are found in bone marrow, mobilized peripheral blood, and umbilical cord blood.
Hematopoietic stem cell transplant (HSCT)
A procedure that replaces a patient’s blood-forming system with hematopoietic stem cells from the patient or a donor after conditioning. It is used for some cancers and bone-marrow failure disorders.
HLA matching
Comparison of human leukocyte antigen (HLA) genes between donor and recipient. Closer HLA matches lower the risk of graft rejection and graft-versus-host disease in allogeneic transplant.
Homologous use
Use of an HCT/P to repair, reconstruct, replace, or supplement a recipient’s cells or tissues that perform the same basic function in the recipient as in the donor, a key factor in U.S. tissue regulation.
Human embryonic stem cell (hESC)
A pluripotent stem cell derived from the inner cell mass of a human blastocyst.
In vitro
Latin for “in glass”; describes work done in a laboratory dish or test tube rather than in a living organism.
Induced pluripotent stem cell (iPSC)
A pluripotent stem cell created by reprogramming a specialized adult cell to an embryonic stem cell–like state. Mouse iPSCs were first reported in 2006 and human iPSCs in 2007.
Inner cell mass (ICM)
The cluster of cells inside the blastocyst that gives rise to the embryo. Inner cell mass cells are the source of embryonic stem cell lines.
Investigational New Drug (IND)
The application filed with the U.S. FDA before a sponsor may begin clinical trials of an unapproved drug or biologic, including many cell and gene therapies, in people.
Mesenchymal stem cells (MSCs)
Multipotent stromal cells found in bone marrow and other tissues that can form bone, cartilage, and fat under laboratory conditions. Many researchers prefer the term mesenchymal stromal cells because the cells are a mixed population and may not meet strict stem cell criteria in every assay.
Minimal manipulation
Processing that does not alter the original relevant characteristics of a cell or tissue related to its utility for reconstruction, repair, or replacement. In U.S. rules, more than minimal manipulation usually means a product needs full biologic approval.
Mobilization
Drug treatment, often with growth factors, that moves blood-forming stem cells from the bone marrow into the bloodstream so they can be collected by apheresis.
Multipotent
Describes a stem cell that can form multiple specialized cell types, usually within one tissue or lineage, but not all cell types of the body.
Neural stem cell
A stem cell in neural tissue that can give rise to neurons and glial cells such as astrocytes and oligodendrocytes.
Niche
The local microenvironment in a tissue that helps control stem cell survival, self-renewal, and differentiation through cell contacts and signals.
Organoid
A three-dimensional culture of stem or progenitor cells that self-organizes into structures resembling a simplified organ and is used to study development, disease, and drugs.
Pluripotent
Describes a stem cell that can form all cell types of the body but not the extra-embryonic tissues of the placenta. Embryonic stem cells and induced pluripotent stem cells are pluripotent.
Prime editing
A gene-editing method that can rewrite short stretches of DNA at a targeted site without requiring a double-strand cut and a separate DNA donor template for many edits.
Progenitor cell
A descendant of a stem cell that is more limited in how many times it can divide and in which cell types it can become. Progenitors help expand a lineage before final differentiation.
Regenerative Medicine Advanced Therapy (RMAT)
A U.S. FDA designation created by the 21st Century Cures Act for regenerative medicine therapies intended to treat serious conditions. It can provide intensified FDA guidance and eligibility for faster review pathways.
Reprogramming
The conversion of a specialized cell into a pluripotent state, or into another cell type, by changing gene activity. Induced pluripotent stem cells are made by reprogramming.
Retinal pigment epithelium (RPE)
A layer of cells in the eye that supports the photoreceptors. RPE cells made from stem cells have been tested in programs for macular degeneration.
Somatic cell
Any body cell other than a gamete (egg or sperm).
Somatic cell nuclear transfer (SCNT)
A technique that places the nucleus of a somatic cell into an egg whose own nucleus has been removed, creating an embryo with the somatic cell’s nuclear DNA. It can be used for research or, in animals, reproductive cloning.
Somatic stem cell
Another name for an adult stem cell: a non-embryonic stem cell found in body tissues. See Adult stem cell.
Stem cell
A cell that can renew itself and give rise to specialized cells. Stem cells include pluripotent cells such as embryonic and induced pluripotent stem cells, and tissue-specific adult stem cells.
Stem cell tourism
Travel to clinics that market unproven stem cell interventions outside rigorous clinical trials or regulatory approval. Medical groups warn that such treatments can be ineffective or harmful.
Stromal cells
Non-blood cells from blood-forming organs such as bone marrow that can support blood-cell growth in culture. Bone-marrow stromal cells that form the tissue matrix are related to mesenchymal stromal cells.
Teratoma
A benign tumor containing differentiated tissues from more than one germ layer. Injection into immune-deficient mice is sometimes used as a test of pluripotency.
Totipotent
Describes a cell that can give rise to all cell types of an organism, including the extra-embryonic tissues of the placenta. In mammals this capacity is limited to the zygote and early cleavage-stage blastomeres.
Umbilical cord blood stem cells
Blood-forming stem cells collected from the umbilical cord at birth. Cord blood is used in transplants for some patients after chemotherapy or for blood disorders.
Unipotent
Describes a stem or progenitor cell that can renew itself but produce only one specialized cell type, such as a spermatogonial stem cell.
Unproven stem cell clinics
Businesses that sell stem cell interventions that are not approved by regulators and are not part of a properly authorized clinical trial. Patients may face infection, immune reactions, or other serious harm.
Urine-derived stem cells
A rare population of self-renewing cells found in urine that were systematically isolated and characterized in the early 2010s, building on earlier observations of exfoliated cells in newborn urine. Their clinical uses remain investigational.
Learn More: Urine-Derived Stem Cells – What They Are and What They Can Actually Do
Yamanaka factors
The four transcription factors Oct4, Sox2, Klf4, and c-Myc that Shinya Yamanaka’s group used to reprogram specialized cells into induced pluripotent stem cells.
